Commercial Partners
International Technical Legacy (ITL)
International Technical Legacy (ITL) holds an exclusive five-year commercial supply agreement covering more than 15 markets across the Middle East and North Africa, together with Türkiye. The agreement includes minimum purchases of 6,000 Felix™ cartridges and the deployment of 10 consoles. ITL has placed initial and repeat orders, including an order for 1,000 cartridges announced in May 2026.
Centro Fertilità Assistita (CFA Italia)
Centro Fertilità Assistita (CFA Italia) is one of Italy’s largest private fertility clinic groups. Memphasys has a five-year commercial supply agreement with CFA Italia, with minimum contracted purchases of approximately A$925,000.
Andro Diagnostics
Andro Diagnostics / ACC holds a five-year non-exclusive supply agreement for India, providing access to a network of more than 200 IVF clinics. The Year 1 minimum is 1,800 cartridges, increasing to at least 2,700 cartridges in Year 2. Commercial activation remains subject to CDSCO regulatory approval.
Australia, Europe and Asia-Pacific
Australia: Memphasys has a 12-month exclusive national supply agreement with Monash IVF Group, initially covering two clinics with a pathway to its broader Australian network.
Japan: A five-year agreement with Vitrolife Japan KK supports the commercial rollout of Felix™, including adoption at Kobe Clinic and subsequent orders.
United Kingdom: Felix™ is being commercially trialled by four UK IVF groups, with initial orders received from multiple sites.
Poland: A European commercialisation agreement is supporting clinic engagement and Felix™ rollout.
Nordic region: NOVIVITAE is the exclusive commercialisation partner across Denmark, Sweden, Norway, Finland and Iceland. The agreement includes minimum contracted purchases of €526,500 over three Agreement Years following an initial evaluation period.
Vietnam: A two-year exclusive commercialisation agreement with TMSC Vietnam has a minimum value of approximately A$530,000. Registration achieved in August 2026 triggered an initial 600-cartridge order, in addition to 100 cartridges previously delivered.
Thailand: The exclusive agreement with IVF Envimed has a minimum value of approximately A$430,000. Thai FDA approval enabled commercial launch and initial orders.
Research & Clinical Validation Partners
The University of Newcastle
The Priority Research Centre for Reproductive Science at the University of Newcastle is the largest research group in the field of reproduction medicine and fertility in Australia, working with humans and across most animal species.
The University of Newcastle (UoN) is internationally recognised for its contribution to human reproduction and fertility. The Priority Research Centre for Reproductive Science (PRCRS) is led by Professor John Aitken, who is internationally recognised for his breakthrough research history in this field.
Monash IVF Group
Serves to support you on every step of your fertility journey
Monash was an early international pioneer in In Vitro Fertilisation (IVF), helping achieve Australia’s first IVF baby, the third in the world, in 1980.
Today Monash IVF is the second largest IVF group in Australia. It was the primary Australian clinical partner for the Memphasys Phase III randomised controlled trial of the Felix™ System and is now Memphasys’ exclusive national supply partner under a 12-month agreement. Initial rollout is across two clinics, with a pathway to Monash IVF’s broader Australian network.